Targeting the Metabotropic Glutamate Receptor mGluR4 for the Treatment of Diseases of the Central Nervous System

Author(s): Michael J. Marino, J. F. Hess, Nigel Liverton

Journal Name: Current Topics in Medicinal Chemistry

Volume 5 , Issue 9 , 2005

Become EABM
Become Reviewer
Call for Editor


Over the last several years a great deal of interest has been focused on the metabotropic glutamate receptors as potential targets for the treatment of a variety of disorders of the central nervous system. Recently, selective agonist or allosteric potentiators of mGluR4, one of the group III mGluRs, have been proposed as potential novel therapeutics for the palliative treatment of Parkinsons disease and some forms of epilepsy. mGluR4 stands out amongst the group III mGluRs due to its relatively restricted localization and apparent role in several key neuronal circuits. Work from a number of laboratories has led to the development of more selective tools for the study of mGluR4, as well as refined models of the structure and function of this receptor. In addition, a growing body of literature suggests that mGluR4 plays a key neuroprotective role in broad spectrum of neurodegenerative disorders. It is hoped that this increased understanding of the role of mGluR4 combined with more detailed structural information will spur the development of better pharmacological tools, and ultimately to novel clinical therapy.

Keywords: mglur, glutamate, parkinsons disease

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2005
Page: [885 - 895]
Pages: 11
DOI: 10.2174/1568026054750263
Price: $65

Article Metrics

PDF: 4